Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dry Eye Syndrome Clear all
Withdrawn Phase 4 Interventional

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

NCT03398018
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
repository corticotropin injection
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Early Phase 1 Interventional

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

NCT04792580
View directory record Official record
Conditions
Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions
Lifitegrast 5% Ophthalmic Solution, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

NCT01027013
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
rebamipide 2% ophthalmic suspension, placebo eye drops
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Waterbury, Connecticut • Louisville, Kentucky • Lewiston, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 20, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

NCT02013791
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Vehicle, Sham, Cyclosporine New Ophthalmic Formulation
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Artesia, California • Glendale, California • Irvine, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tear Film Break-up Time After Instillation of Artificial Tears

NCT00681265
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
glycerin, polyethylene glycol 400/propylene glycol
Drug
Lead sponsor
Calm Water Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Phase 2b Controlled Study

NCT07140380
View directory record Official record
Conditions
Dry Eye Disease
Interventions
IVW-1001 Ophthalmic Eyelid Wipe
Drug
Lead sponsor
IVIEW Therapeutics Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multi-Colored Placido Disk Viability

NCT02148497
View directory record Official record
Conditions
Dry Eye, Sjogren's Disease, Healthy
Interventions
Multi-colored Placido disk imaging
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation

NCT01128049
View directory record Official record
Conditions
Aqueous Deficient Dry Eye, Meibomium Gland Dysfunction
Interventions
Subjective Questionnaire, Measurement with wavefront sensor (right eye, then left eye), Instill Saline Drop
Behavioral · Procedure · Drug
Lead sponsor
University of Rochester
Other
Eligibility
20 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Oct 20, 2026, 10:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals

NCT05763940
View directory record Official record
Conditions
Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
Interventions
OmegaBoost, Nature Made (soft gel), Nature Made (gummy)
Dietary Supplement
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 10:14 PM EDT
Recruiting Phase 4 Interventional

Evaluation of Lacrifill

NCT07796178
View directory record Official record
Conditions
Dry Eye, Ocular Surface Disease, Cataract Surgery, Eyes Dry Feeling of
Interventions
Lacrifill, Saline
Drug
Lead sponsor
Eye Research Associates, LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Pittsburg, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the TearCare System in Dry Eye Disease

NCT03588624
View directory record Official record
Conditions
Dry Eye
Interventions
TearCare
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Newport Beach, California • Arlington Heights, Illinois • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 20, 2026, 10:14 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Sustained Reading on the Ocular Surface

NCT02031172
View directory record Official record
Conditions
Dry Eye Syndromes, Sjogren's Syndrome
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
50 Years to 89 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 20, 2026, 10:14 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT)

NCT07281950
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
acoltremon 0.003%
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 4 Interventional

Comparison of Systane Free vs. Saline in the Treatment of Dry Eye

NCT00388791
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Free
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 20, 2026, 10:14 PM EDT
Terminated Not applicable Interventional Results available

Management of Signs and Symptoms Associated With Dry Eye Disease

NCT04015219
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Self retained cryopreserved amniotic membrane, lifitegrast ophthalmic solution
Device · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT05896670
View directory record Official record
Conditions
Dry Eye Disease
Interventions
licaminlimab, vehicle of OCS-02, Artificial tears
Drug · Other
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Newport Beach, California • Colorado Springs, Colorado • Shelby, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome

NCT00637793
View directory record Official record
Conditions
Xerostomia, Sjogren's Syndrome
Interventions
NGX267
Drug
Lead sponsor
TorreyPines Therapeutics
Industry
Eligibility
21 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Duncansville, Pennsylvania • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

NCT00370747
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Ecabet, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

NCT04795752
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • La Jolla, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Designed to Evaluate Tear Production

NCT06544707
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Recruiting No phase listed Observational

Comparative Assessment of Lipid Layer Thickness Measurements

NCT07579130
View directory record Official record
Conditions
Dry Eye
Interventions
LipiView, Omnicad, Bruder Ocular Surface Analyzer
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®

NCT02554981
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine 0.05% Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

e-Mobile Tablet for People With Chronic Conditions

NCT02833311
View directory record Official record
Conditions
Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome, Parkinson's Disease
Interventions
Computer Tablet Group, Paper and Pencil Group, Contact Control Group
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 76 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 20, 2026, 10:14 PM EDT